COMPARATIVE STUDY ON CLINICAL EFFICACY AND SAFETY OF FORMULATED AND MARKETED MYRRH EXTRACT IN CAPSULES
Objective: The development of myrrh extract from natural origin capable of eradicating schistosomal infection has gained the interest of many scientists. Recently, myrrh extract is considered as the drug of choice from natural origin used to treat schistosomiasis. This study was performed to evaluate the safety and efficacy of hard gelatin capsules of myrrh extract in the treatment of Schistosoma mansoni compared to Mirazid which is the only herbal drug present in the market.
Methods: In the present study, the clinical evaluation of different doses of formulated myrrh extract hard gelatin capsules against different grades of S. mansoni infections (mild, moderate, and heavy) was carried out and compared with marketed soft gelatin capsules Mirazid.
Results: In all types of S. mansoni infection, it was clear that the efficacy of n-hexane and alcohol myrrh extracts hard gelatin capsules was higher than or equal to that of Mirazid soft gelatin capsules.
Conclusion: Hard gelatin capsules of myrrh extract (mixed doses) are more effective and more economic as a pharmaceutical dosage form for pharmaceutical manufacturers than Mirazid soft gelatin capsules. Consequently, with its lower price, it can reach the poor patient which is the main patient of schistosomiasis.
2. Dias LC, Pedro RJ, Rigo E, Goto MM, Mafra GL. A human strain of Schistosoma mansoni resistant to schistosomicides. Rev Saude Publica 1978;12:110.
3. Gryseels B, Polderman AM. Morbidity, due to Schistosoma mansoni, and its control in Sub-Saharan Africa. Parasitol Today 1991;7:244-8.
4. Fallon PG, Mubarak JS, Fookes RE, Niang M, Butterworth AE, Sturrock RF, et al. Schistosoma mansoni: Maturation rate and drug susceptibility of different geographic isolates. Exp Parasitol 1997;86:29-36.
5. Van der Werf MJ, de vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, Habbema JD, et al. Quantification of clinical morbidity associated with schistosome infection in Sub-Saharan Africa. Acta Trop 2003;86:125 39.
6. Scott J. The incidence and distribution of the human schistosomiasis in Egypt. Am J Hyg 1937;25:566-614.
7. El-Sharkawy A, El-Toukhy M, Abdel-Rahman SZ, El-Kholy Z, Farag H, El-Zoghby S, et al. An experimental study on the effect of praziquantel and oltipraz on some lysosomal enzymes. J Trop Med Hyg 1993;96:28-34.
8. Herrera LA, Ostrosky-Wegman P, Montero R, Rojas E, Gonsebatt ME, Schiffmann D. Evaluation of the carcinogenic and genotoxic potential of praziquantel in the syrian hamster embryo cell transformation assay. Mutat Res 1994;305:175-80.
9. Rosenkranz HS, Zhang YP, Klopman G. Studies on the potential for genotoxic carcinogenicity of fragrances and other chemicals. Food Chem Toxicol 1998;36:687-96.
10. Rosenkranz HS, Zhang YP, Macina OT, Mattison DR, Klopman G. Human developmental toxicity and mutagenesis. Mutat Res 1998;422:347-50.
11. Montero R, Gonsebatt ME, Herrera LA, Rojas E, Ostrosky-Wegman P. The HPRT short-term assay in monitoring individuals exposed to genotoxic agents. Environ Health Perspect 1993;101 Suppl 3:135-8.
12. Kheir WM, Elsheikh HA, Hapke HJ. The effect of praziquantel on the activities of some drug-metabolizing hepatic enzymes in rabbits. Dtsch Tierarztl Wochenschr 1995;102:84-6.
13. Tonelli SM, Goulart EM, Tonelli E, Coelho PM. Lethal effect of oxamniquine and praziquantel on mice experimentally infected with Schistosoma mansoni. Rev inst med trop sao paulo 1995;37:361-3.
14. Watt G, White NJ, Padre L, Ritter W, Fernando MT, Ranoa CP, et al. Praziquantel pharmacokinetics and side effects in Schistosoma japonicum-infected patients with liver disease. J Infect Dis 1988;157:530-5.
15. Al-Harbi MM, Qureshi S, Ahmed MM, Rafatullah S, Shah AH. Effect of Commiphora molmol (oleo-gum-resin) on the cytological and biochemical changes induced by cyclophosphamide in mice. Am J Chin Med 1994;22:77-82.
16. Massoud A, El Sisi S, Salama O, Massoud A. Preliminary study of therapeutic efficacy of a new fasciolicidal drug derived from Commiphora molmol (Myrrh). Am J Trop Med Hyg 2001;65:96-9.
17. Massoud AA, Hussein HM, Reda MA, El-Wakil HS, Maher KM, Mahmoud FS. Schistosoma mansoni egg specific antibodies and circulating antigens: assessment of their validity in immunodiagnosis of schistosomiasis. J Egypt Soc Parasitol 2000;30:903-16.
18. Hashem F, Massoud A, Melokheya A, Emad H, Badr K, Dawoud M. Formulation and clinical efficacy of myrrh extract in hard gelatin capsules. J Biol Active Prod From Nat 2013;3:72-86.
19. Michelson MK, Azziz FA, Gamil FM, Wahid AA, Richards FO, Juranek DD, et al. Recent trends in the prevalence and distribution of schistosomiasis in the nile delta region. Am J Trop Med Hyg 1993;49:76-87.
20. Katz N, Chaves A, Pellegrino J. A simple device for quantitative stool thick-smear technique in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 1972;14:397-400.
21. Martin LK, Beaver PC. Evaluation of kato thick-smear technique for quantitative diagnosis of helminth infections. Am J Trop Med Hyg 1968;17:382-91.
22. EL Ashry ER, Salama O. Colorimetric determination of crude powdered myrrh, purified myrrh extract, oily fraction, and its pharmaceutical dosage forms. Spectrosc Lett 2002;35:183-97.
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.